Clinical Outcomes and Prognostic Factors of Empirical Antifungal Therapy with Itraconazole in the Patients with Hematological Malignancies: A Prospective Multicenter Observational Study in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To identify prognostic factors for the outcomes of empirical antifungal therapy, we performed a multicenter, prospective, observational study in immunocompromised patients with hematological malignancies. Materials and Methods: Three hundred seventy-six patients (median age of 48) who had neutropenic fever and who received intravenous (IV) itraconazole as an empirical antifungal therapy for 3 or more days were analyzed. The patients with possible or probable categories of invasive fungal disease (IFD) were enrolled. Results: The overall success rate was 51.3% (196/376). Age >50 years, underlying lung disease (co-morbidity), poor performance status [Eastern Cooperative Oncology Group (ECOG) ≥2], radiologic evidence of IFD, longer duration of baseline neutropenic fever (≥4 days), no antifungal prophylaxis or prophylactic use of antifungal agents other than itraconazole, and high tumor burden were associated with decreased success rate in univariate analysis. In multivariate analysis, age >50 years (p=0.009) and poor ECOG performance status (p=0.005) were significantly associated with poor outcomes of empirical antifungal therapy. Twenty-two patients (5.9%) discontinued itraconazole therapy due to toxicity. Conclusion: We concluded that empirical antifungal therapy with IV itraconazole in immunocompromised patients is effective and safe. Additionally, age over 50 years and poor performance status were poor prognostic factors for the outcomes of empirical antifungal therapy with IV itraconazole.
Abstract
Purpose: To identify prognostic factors for the outcomes of empirical antifungal therapy, we performed a multicenter, prospective, observational study in immunocompromised patients with hematological malignancies. Materials and Methods: Three hundred seventy-six patients (median age of 48) who had neutropenic fever and who received intravenous (IV) itraconazole as an empirical antifungal therapy for 3 or more days were analyzed. The patients with possible or probable categories of invasive fungal disease (IFD) were enrolled. Results: The overall success rate was 51.3% (196/376). Age >50 years, underlying lung disease (co-morbidity), poor performance status [Eastern Cooperative Oncology Group (ECOG) ≥2], radiologic evidence of IFD, longer duration of baseline neutropenic fever (≥4 days), no antifungal prophylaxis or prophylactic use of antifungal agents other than itraconazole, and high tumor burden were associated with decreased success rate in univariate analysis. In multivariate analysis, age >50 years (p=0.009) and poor ECOG performance status (p=0.005) were significantly associated with poor outcomes of empirical antifungal therapy. Twenty-two patients (5.9%) discontinued itraconazole therapy due to toxicity. Conclusion: We concluded that empirical antifungal therapy with IV itraconazole in immunocompromised patients is effective and safe. Additionally, age over 50 years and poor performance status were poor prognostic factors for the outcomes of empirical antifungal therapy with IV itraconazole.
참고문헌 (30)
- Upton A, "Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient", Curr Infect Dis Rep, 8, pp.434~441 (2006)
- Pagano L, "The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study", Haematologica, 91, pp.1068~1075 (2006)
- Pagano L, "Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study", Haematologica, 95, pp.644~650 (2010)
- Wingard JR, "Empirical antifungal therapy in treating febrile neutropenic patients", Clin Infect Dis, 39(Suppl 1), pp.S38~S43 (2004)
- Cordonnier C, "Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial", Clin Infect Dis, 48, pp.1042~1051 (2009)
- Boogaerts M, "Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial", Ann Intern Med, 135, pp.412~422 (2001)
- Sun Hee Park, "Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever", The Korean Journal of Internal Medicine, 21(3), pp.165~172 (2006), 대한내과학회
- Walsh TJ, "Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.327~360 (2008)
- Maertens J, "European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update", Bone Marrow Transplant, 46, pp.709~718 (2011)
- 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
- Klastersky J, "Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?", N Engl J Med, 351, pp.1445~1447 (2004)
- Schuler U, "Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy", Onkologie, 30, pp.185~191 (2007)
- Ohta K, "Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan", Int J Hematol, 89, pp.649~655 (2009)
- Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America", Clin Infect Dis, 52, pp.427~431 (2011)
- Ascioglu S, "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clin Infect Dis, 34, pp.7~14 (2002)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Greenberg P, "International scoring system for evaluating prognosis in myelodysplastic syndromes", Blood, 89, pp.2079~2088 (1997)
- "A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project", N Engl J Med, 329, pp.987~994 (1993)
- Borchmann P, "State of the art in the treatment of Hodgkin lymphoma", Nat Rev Clin Oncol, 9, pp.450~459 (2012)
- Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
- Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective", Biol Blood Marrow Transplant, 15, pp.1143~1238 (2009)
- Walsh TJ, "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group", N Engl J Med, 340, pp.764~771 (1999)
- Walsh TJ, "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", N Engl J Med, 346, pp.225~234 (2002)
- Walsh TJ, "Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia", N Engl J Med, 351, pp.1391~1402 (2004)
- Common terminology criteria for adverse events (CTCAE) v3.0, , National Cancer Institute, ~ (2006)
- Maertens J, "Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation", Blood, 97, pp.1604~1610 (2001)
- Maertens JA, "Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay", Clin Infect Dis, 44, pp.1329~1336 (2007)
- "Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group", Am J Med, 86(6 Pt 1), pp.668~672 (1989)
- Wingard JR, "Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation", Blood, 116, pp.5111~5118 (2010)
- Glasmacher A, "Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole", Mycoses, 42, pp.443~451 (1999)